Paul Marshall

Paul Marshall discloses dealings in 2 companies, chiefly Amylin Pharmaceuticals Inc and Heron Therapeutics, Inc. /DE/. The record holds 22 filings, for trades running from 1 February 2008 to 21 March 2016.

Every open-market trade on record is a sale: 3 sales worth €1.0M. Outside the open market, there are 11 share grants and 3 option exercises.

The newest entry dates from 23 March 2016: an option exercise of €8,826, in Heron Therapeutics, Inc. /DE/. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.